Puma Biotechnology, Inc. (PBYI) Balance Sheet
PBYI balance sheet, 2025
December 31, 2025 · U.S. dollars$216.3M assets = $86.0M liabilities + $130.3M equity
Both columns are drawn to the same scale: what PBYI owns equals what it owes plus shareholders’ equity. Hover a block for its value.
PBYI financial health
Descriptive bands, not a rating. Fiscal 2025.
PBYI balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $252.8M2016 | $216.3M2025 | −1.7%/yr | |
| Total liabilities | $43.0M2016 | $86.0M2025 | +8.0%/yr | |
| Shareholders’ equity | $209.8M2016 | $130.3M2025 | −5.2%/yr | |
| Cash & short-term investments | $194.5M2016 | $97.5M2025 | −7.4%/yr | |
| Total debt | $48.5M2017 | $28.5M2025 | −6.4%/yr | |
| Net cash (debt) | $33.2M2017 | $69.0M2025 | +$35.8M | |
| Working capital | $199.0M2016 | $81.4M2025 | −$117.6M | |
| Book value per share | $6.302016 | $2.572025 | −9.5%/yr | |
| Current ratio | 6.312016 | 2.002025 | −4.31 | |
| Debt / equity | 0.912017 | 0.222025 | −0.69 | |
| Shares outstanding | 33.3M2016 | 50.7M2025 | +4.8%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PBYI assets
PBYI liabilities and equity
PBYI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
PBYI balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $97.5M | $101.0M | $95.9M | $81.1M | $82.1M | $93.4M | $111.6M | $108.4M | $81.7M | $194.5M |
| Cash & equivalents | $29.6M | $69.2M | $84.6M | $76.2M | $63.1M | $85.3M | $60.0M | $108.4M | $81.7M | $194.5M |
| Short-term investments | $67.9M | $31.7M | $11.4M | $4.9M | $19.0M | $8.1M | $51.6M | $57.0M | $0 | $35.0M |
| Receivables | $53.7M | $32.0M | $48.5M | $42.3M | $32.5M | $25.5M | $28.9M | $21.9M | $9.7M | $0 |
| Inventory | $5.5M | $8.7M | $7.1M | $4.5M | $7.1M | $3.5M | $3.2M | $2.6M | $2.0M | $0 |
| Other current assets | $6.0M | $6.0M | $4.7M | $6.4M | $18.3M | $23.8M | $22.6M | $70.0M | $13.0M | $42.0M |
| Total current assets | $162.7M | $147.7M | $156.2M | $134.3M | $140.0M | $146.1M | $166.3M | $203.0M | $106.4M | $236.5M |
| Property, plant & equipment (net) | $5.6M | $5.1M | $8.6M | $12.5M | $15.8M | $18.9M | $21.8M | $4.0M | $4.5M | $5.2M |
| Goodwill & intangible assets | $41.4M | $51.1M | $60.9M | $70.6M | $66.1M | $74.1M | $40.5M | $44.4M | $48.4M | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $6.7M | $9.4M | $4.8M | $4.7M | $4.7M | $5.1M | $6.3M | $7.7M | $6.3M | $11.2M |
| Total assets | $216.3M | $213.3M | $230.5M | $222.1M | $226.6M | $244.2M | $234.9M | $259.1M | $165.5M | $252.8M |
| Liabilities | ||||||||||
| Accounts payable | $5.1M | $5.5M | $6.9M | $6.4M | $11.2M | $12.1M | $19.2M | $20.7M | $27.7M | $20.0M |
| Short-term debt | $23.8M | $50.9M | $38.8M | $4.1M | $3.6M | $17.4M | $2.6M | — | $48.5M | — |
| Deferred revenue | — | — | — | $5.9M | $92.6M | $82.3M | — | — | — | — |
| Total current liabilities | $81.3M | $96.1M | $99.4M | $77.5M | $109.6M | $114.3M | $90.8M | $67.1M | $58.3M | $37.5M |
| Long-term debt | $0 | $21.7M | $65.7M | $98.3M | $97.1M | $84.0M | $95.0M | $151.9M | $48.5M | $0 |
| Lease obligations | $6.0M | $7.0M | $11.8M | $16.0M | $19.5M | $22.6M | $25.3M | — | — | — |
| Other long-term liabilities | $4.7M | $3.4M | $12.0M | $24.7M | $22.4M | $51.9M | $31.6M | $5.8M | $5.4M | $5.5M |
| Total liabilities | $86.0M | $121.2M | $177.1M | $200.5M | $229.0M | $250.2M | $217.4M | $224.8M | $112.2M | $43.0M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $5,000 | $5,000 | $5,000 | $5,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 |
| Retained earnings (deficit) | −$1.28B | −$1.31B | −$1.35B | −$1.37B | −$1.37B | −$1.34B | −$1.28B | −$1.20B | −$1.09B | −$796.5M |
| Treasury stock | — | — | — | — | — | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | $36,000 | $6,000 | −$4,000 | $0 | −$2,000 | $0 | $62,000 | −$12,000 | −$4.1M | −$13,000 |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $130.3M | $92.1M | $53.4M | $21.6M | −$2.4M | −$6.0M | $17.5M | $34.3M | $53.3M | $209.8M |
| Key figures | ||||||||||
| Total debt | $28.5M | $74.1M | $111.5M | $114.3M | $116.6M | $121.0M | $120.2M | $151.9M | $48.5M | — |
| Net cash (debt) | $69.0M | $26.9M | −$15.6M | −$33.2M | −$34.5M | −$27.6M | −$8.6M | −$43.5M | $33.2M | — |
| Working capital | $81.4M | $51.5M | $56.8M | $56.8M | $30.4M | $31.9M | $75.5M | $135.9M | $48.1M | $199.0M |
| Tangible book value | $88.9M | $41.0M | −$7.4M | −$49.0M | −$68.6M | −$80.1M | −$23.0M | −$10.1M | $4.9M | $209.8M |
| Book value per share | $2.57 | $1.88 | $1.12 | $0.48 | −$0.06 | −$0.15 | $0.45 | $0.90 | $1.43 | $6.30 |
| Shares outstanding | 50.7M | 49.1M | 47.6M | 44.9M | 40.6M | 39.6M | 38.8M | 37.9M | 37.2M | 33.3M |
| Current ratio | 2.00 | 1.54 | 1.57 | 1.73 | 1.28 | 1.28 | 1.83 | 3.02 | 1.82 | 6.31 |
| Quick ratio | 1.86 | 1.38 | 1.45 | 1.59 | 1.05 | 1.04 | 1.55 | 1.94 | 1.57 | 5.19 |
| Debt / equity | 0.22 | 0.80 | 2.09 | 5.29 | — | — | 6.88 | 4.43 | 0.91 | — |
| Equity / assets | 60.3% | 43.2% | 23.2% | 9.7% | −1.1% | −2.4% | 7.4% | 13.2% | 32.2% | 83.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $93.9M | $101.5M | $97.5M | $94.4M | $96.0M | $93.2M | $101.0M | $96.7M | $96.8M | $107.2M | $95.9M | $85.0M |
| Cash & equivalents | $36.5M | $36.2M | $29.6M | $53.5M | $54.7M | $63.0M | $69.2M | $67.3M | $67.1M | $76.8M | $84.6M | $81.8M |
| Short-term investments | $57.4M | $65.4M | $67.9M | $40.9M | $41.4M | $30.1M | $31.7M | $29.5M | $29.7M | $30.4M | $11.4M | $3.2M |
| Receivables | $34.1M | $26.3M | $53.7M | $33.6M | $25.9M | $25.2M | $32.0M | $54.6M | $28.1M | $24.6M | $48.5M | $29.0M |
| Inventory | $13.3M | $8.7M | $5.5M | $9.5M | $8.6M | $8.8M | $8.7M | $2.7M | $9.0M | $7.1M | $7.1M | $5.7M |
| Other current assets | $3.8M | $5.7M | $6.0M | $6.2M | $6.1M | $5.4M | $6.0M | $2.8M | $3.7M | $4.2M | $4.7M | $5.7M |
| Total current assets | $145.1M | $142.3M | $162.7M | $143.6M | $136.6M | $132.5M | $147.7M | $156.8M | $137.7M | $143.0M | $156.2M | $125.4M |
| Property, plant & equipment (net) | $4.5M | $4.7M | $5.6M | $6.5M | $3.2M | $4.2M | $5.1M | $6.0M | $6.9M | $7.8M | $8.6M | $9.4M |
| Goodwill & intangible assets | $36.5M | $39.0M | $41.4M | $43.8M | $46.3M | $48.7M | $51.1M | $53.6M | $56.0M | $58.4M | $60.9M | $63.3M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $6.6M | $6.8M | $6.7M | $9.0M | $8.9M | $10.8M | $9.4M | $4.3M | $4.4M | $4.9M | $4.8M | $5.5M |
| Total assets | $192.7M | $192.7M | $216.3M | $202.9M | $194.9M | $196.2M | $213.3M | $220.7M | $205.0M | $214.1M | $230.5M | $203.6M |
| Liabilities | ||||||||||||
| Accounts payable | $3.1M | $8.2M | $5.1M | $6.4M | $5.4M | $6.0M | $5.5M | $7.5M | $13.5M | $9.0M | $6.9M | $5.1M |
| Short-term debt | $450,000 | $11.4M | $23.8M | $36.2M | $38.4M | $51.1M | $50.9M | $50.7M | $50.5M | $50.3M | $38.8M | $27.3M |
| Deferred revenue | — | — | — | — | — | — | — | — | — | — | — | $33.8M |
| Total current liabilities | $49.8M | $59.7M | $81.3M | $82.7M | $79.1M | $86.7M | $96.1M | $110.4M | $104.3M | $98.2M | $99.4M | $67.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $10.9M | $10.6M | $21.7M | $32.7M | $43.7M | $54.7M | $65.7M | $76.6M |
| Lease obligations | $4.8M | $4.7M | $6.0M | $7.3M | $4.4M | $5.7M | $7.0M | $8.3M | $9.5M | $10.7M | $11.8M | $12.9M |
| Other long-term liabilities | $4.4M | $4.5M | $4.7M | $4.9M | $230,000 | $1.8M | $3.4M | $6.5M | $8.5M | $10.3M | $12.0M | $20.9M |
| Total liabilities | $54.2M | $64.3M | $86.0M | $87.6M | $90.2M | $99.1M | $121.2M | $149.6M | $156.5M | $163.2M | $177.1M | $164.9M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 |
| Retained earnings (deficit) | −$1.28B | −$1.29B | −$1.28B | −$1.30B | −$1.31B | −$1.31B | −$1.31B | −$1.33B | −$1.35B | −$1.35B | −$1.35B | −$1.36B |
| Accumulated other comprehensive income | −$45,000 | −$31,000 | $36,000 | $18,999 | −$14,000 | −$11,000 | $6,000 | $26,000 | −$32,000 | −$26,000 | −$4,000 | −$4,000 |
| Total shareholders' equity | $138.5M | $128.4M | $130.3M | $115.3M | $104.7M | $97.1M | $92.1M | $71.1M | $48.5M | $51.0M | $53.4M | $38.7M |
| Key figures | ||||||||||||
| Total debt | $4.8M | $16.0M | $28.5M | $41.1M | $49.2M | $61.7M | $74.1M | $86.4M | $98.6M | $110.7M | $111.5M | $112.2M |
| Net cash (debt) | $89.1M | $85.6M | $69.0M | $53.3M | $46.8M | $31.5M | $26.9M | $10.4M | −$1.8M | −$3.6M | −$15.6M | −$27.2M |
| Working capital | $95.2M | $82.5M | $81.4M | $60.9M | $57.5M | $45.8M | $51.5M | $46.4M | $33.4M | $44.8M | $56.8M | $58.0M |
| Tangible book value | $102.0M | $89.5M | $88.9M | $71.4M | $58.5M | $48.4M | $41.0M | $17.5M | −$7.5M | −$7.5M | −$7.4M | −$24.6M |
| Book value per share | $2.63 | $2.53 | $2.53 | $2.26 | $2.09 | $1.95 | $1.86 | $1.45 | $1.00 | $1.06 | $1.11 | $0.81 |
| Shares outstanding | 52.6M | 50.8M | 51.5M | 50.9M | 50.1M | 49.9M | 49.4M | 49.2M | 48.3M | 48.2M | 48.0M | 47.8M |
| Current ratio | 2.91 | 2.38 | 2.00 | 1.74 | 1.73 | 1.53 | 1.54 | 1.42 | 1.32 | 1.46 | 1.57 | 1.86 |
| Quick ratio | 2.57 | 2.14 | 1.86 | 1.55 | 1.54 | 1.37 | 1.38 | 1.37 | 1.20 | 1.34 | 1.45 | 1.69 |
| Debt / equity | 0.03 | 0.12 | 0.22 | 0.36 | 0.47 | 0.64 | 0.80 | 1.21 | 2.03 | 2.17 | 2.09 | 2.90 |
| Equity / assets | 71.9% | 66.6% | 60.3% | 56.8% | 53.7% | 49.5% | 43.2% | 32.2% | 23.7% | 23.8% | 23.2% | 19.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.
PBYI financial position
At the end of fiscal 2025 (December 31, 2025), Puma Biotechnology had total assets of $216.3 million (up 1.4% from a year earlier), total liabilities of $86.0 million and shareholders' equity of $130.3 million. It held $97.5 million in cash and short-term investments against $28.5 million of debt, a net cash position of $69.0 million. Its current ratio was 2.00. In the latest quarter (ended June 30, 2026) total assets were $192.7 million and equity $138.5 million.
Related: PBYI income statement, PBYI cash flow statement, PBYI key metrics. See the PBYI stock overview for the latest quote and news.
PBYI balance sheet FAQ
What are Puma Biotechnology's total assets?
Puma Biotechnology reported total assets of $216.3 million at the end of fiscal 2025 (December 31, 2025), compared with $213.3 million a year earlier.
How much debt does Puma Biotechnology have?
Puma Biotechnology had $28.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.22.
How much cash does Puma Biotechnology have?
Puma Biotechnology held $97.5 million in cash and short-term investments at the end of fiscal 2025; with $28.5 million of debt that is net cash of $69.0 million.
What is Puma Biotechnology's book value?
Puma Biotechnology's shareholders' equity (book value) was $130.3 million at the end of fiscal 2025, or $2.57 per share.
What is Puma Biotechnology's current ratio?
Puma Biotechnology had current assets of $162.7 million and current liabilities of $81.3 million, a current ratio of 2.00 (it can cover its short-term obligations).
How much goodwill does Puma Biotechnology have?
Puma Biotechnology carried $41.4 million of goodwill and intangible assets, 19.1% of total assets, at the end of fiscal 2025.